Relay Therapeutics, Inc.
General ticker "RLAY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Relay Therapeutics, Inc. follows the US Stock Market performance with the rate: 57.4%.
Estimated limits based on current volatility of 3.5%: low 18.74$, high 20.09$
Factors to consider:
- Total employees count: 192 (-26.4%) as of 2025
- Top business risk factors: Clinical trial failure, Market competition, Regulatory and compliance, Inability to raise capital, Labor/talent shortage/retention
- Current price 50.7% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.19$, 13.21$]
- 2026-12-31 to 2027-12-31 estimated range: [3.95$, 10.33$]
Financial Metrics affecting the RLAY estimates:
- Positive: with PPE of -5.2 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 91.27 > 64.23
- Negative: Industry earnings per price (median), % of -13.64 <= 0
Short-term RLAY quotes
Long-term RLAY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $25.55MM | $10.01MM | $15.36MM |
| Operating Expenses | $398.55MM | $382.48MM | $318.09MM |
| Operating Income | $-373.00MM | $-372.47MM | $-302.74MM |
| Non-Operating Income | $31.06MM | $34.73MM | $26.26MM |
| R&D Expense | $330.02MM | $319.09MM | $261.38MM |
| Income(Loss) | $-341.94MM | $-337.74MM | $-276.48MM |
| Net Income(Loss)* | $-341.97MM | $-337.71MM | $-276.48MM |
| Stockholders Equity | $752.00MM | $777.79MM | $567.06MM |
| Assets | $843.98MM | $871.30MM | $621.33MM |
| Operating Cash Flow | $-300.32MM | $-249.11MM | $-235.46MM |
| Capital expenditure | $4.13MM | $2.02MM | $0.41MM |
| Investing Cash Flow | $257.63MM | $-41.08MM | $192.80MM |
| Financing Cash Flow | $34.75MM | $270.15MM | $1.60MM |
| Earnings Per Share** | $-2.79 | $-2.36 | $-1.61 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.